Lawsuit Filed Against Capricor Therapeutics Over Alleged Securities Violations
A lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) by an investor alleging violations of securities laws due to misleading statements and undisclosed changes in the statistical analysis plan for its drug Deramiocel. The plaintiff claims that these actions created a significant risk regarding regulatory approval from the FDA for treating Duchenne muscular dystrophy. Investors who purchased shares are advised to contact The Shareholders Foundation, Inc., which is assisting with legal monitoring but not representing any law firm or initiating litigation itself. Investors have until September 28, 2026, to act on this matter.
Tickers: $CAPR
Topics: clinical trial data FDA approval risk lawsuit securities_fraud